SIRPA and cancer: We performed an additional in silico analysis of TIM3, LAG3, TIGIT, B7-H6 and CD47-SIRPa to explore the correlation of these markers of immunomodulation in situ by using the online platform TIMER, which is based on 10,897 samples across 32 cancer types from The Cancer Genome Atlas (TCGA) [118].